share_log

恒瑞医药被赚差价？业内：中国BD市场尚在“补课”

Did Hengrui Pharmaceutical get the price difference? Industry: China's BD market is still “making up lessons”

Moomoo 24/7 ·  Jan 14 20:35
Recently, British pharmaceutical company GlaxoSmithKline (GSK.US) announced the acquisition of Aiolos Bio, an American clinical-stage biopharmaceutical service provider, with a down payment of 1 billion US dollars and a milestone payment of 400 million US dollars. GSK targets Aiolos Bio's only core pipeline — the monoclonal antibody AIO-001 for treating asthma in adults. The IO-001 pipeline was not self-developed by Aiolos Bio; it was authorized by Hengrui Pharmaceutical, the first brother of Chinese medicine. Pharmaceutical analysts said that overall, in the current AIO-001 monoclonal antibody deal, the so-called “middleman earns the price difference” claim is suspected of being hyped up by the media. On the opinion that “Hengrui Pharmaceuticals can easily take action,” he said, “One (Aiolos Bio) is gambling, betting, and taking big orders every few years; one (Hengrui Pharmaceutical) is a way for the manufacturing industry to increase overseas. It's not a business that everyone is doing at all; Hengrui still makes money.” (Surge News)
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment